SS.MNS-(D2Mit6-D2Rat303)/Ayd |
receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio |
Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 13 |
19.33 |
% |
3.67 |
13.23 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
69066 |
1096 |
SS/Jr |
receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio |
Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) and NG-nitroarginine methyl ester (100 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 12 |
50.61 |
% |
5.29 |
18.33 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
69069 |
1096 |
SS.MNS-(D2Mit6-D2Rat303)/Ayd |
logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50) |
Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) and NG-nitroarginine methyl ester (100 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 13 |
-7.2 |
null |
0.31 |
1.12 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
69072 |
1096 |
SS/Jr |
receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio |
Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 12 |
34.85 |
% |
2.94 |
10.18 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
69065 |
1096 |
SS/Jr |
logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50) |
Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 12 |
-8.22 |
null |
0.26 |
0.9 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
69067 |
1096 |
SS.MNS-(D2Mit6-D2Rat303)/Ayd |
logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50) |
Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 13 |
-7.86 |
null |
0.27 |
0.97 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
69068 |
1096 |
SS/Jr |
logarithm of the concentration of angiotensin II at which the force of blood vessel contraction is half the maximum value (Log EC50) |
Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) then NG-nitroarginine methyl ester (100 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 12 |
-7.92 |
null |
0.36 |
1.25 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
69071 |
1096 |
SS.MNS-(D2Mit6-D2Rat303)/Ayd |
receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio |
Kreb's solution perfusate then angiotensin II (0.3-300 umol/l) and NG-nitroarginine methyl ester (100 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 13 |
26.63 |
% |
4.0 |
14.42 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
69070 |
1096 |